American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 916-929 , November 2008

Cost-Effectiveness of Breast Cancer Screening in Women on Dialysis

  • Germaine Wong, MBBS, MMed(Clin Epi)

      Affiliations

    • NHMRC Centre for Clinical Research Excellence in Renal Medicine, Children's Hospital at Westmead, Westmead, NSW, Australia
    • School of Public Health, University of Sydney, Sydney, Australia
    • Corresponding Author InformationAddress correspondence to Germaine Wong, MBBS, MMed(Clin Epi), Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW 2145, Australia
    • ,
  • Kirsten Howard, MAppSc(Biopharm), MHthEcon, MPH, PhD

      Affiliations

    • School of Public Health, University of Sydney, Sydney, Australia
    • ,
  • Jeremy R. Chapman, MD

      Affiliations

    • Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW, Australia
    • ,
  • Jonathan C. Craig, MD, PhD

      Affiliations

    • NHMRC Centre for Clinical Research Excellence in Renal Medicine, Children's Hospital at Westmead, Westmead, NSW, Australia
    • School of Public Health, University of Sydney, Sydney, Australia

Received 17 March 2008 ,Accepted 4 June 2008.

References 

  1. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews. 2006;4:CD001877
  2. Andersson I, Janzon L, Sigfusson BF. Mammographic breast cancer screening—A randomized trial in Malmo, Sweden. Maturitas. 1985;7:21–29
  3. Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer. 1977;39(suppl 82):2323–2964
  4. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am. 1992;30:187–210
  5. Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: Mammograms and physical examinations. J Clin Oncol. 2001;19:3490–3499
  6. Gyrd-Hansen D, Holund B, Andersen P. A cost-effectiveness analysis of cervical cancer screening: Health policy implications. Health Policy. 1995;34:35–51
  7. Hall J, Gerard K, Salkeld G, Richardson J. A cost utility analysis of mammography screening in Australia. Soc Sci Med. 1992;34:993–1004
  8. Leivo T, Sintonen H, Tuominen R, Hakama M, Pukkala E, Heinonen OP. The cost-effectiveness of nationwide breast carcinoma screening in Finland, 1987-1992. Cancer. 1999;86:638–646
  9. Lindfors KK, Rosenquist CJ. The cost-effectiveness of mammographic screening strategies. JAMA. 1995;274:881–884
  10. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296:2823–2831
  11. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. Solid organ cancers: Prevention and treatment. Nephrol Dial Transplant. 2002;17(Suppl 4):32;34-36
  12. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients (American Society of Transplantation). J Am Soc Nephrol. 2000;11(suppl 86):S1–S86
  13. Winkelmayer WC, Owen W, Glynn RJ, Levin R, Avorn J. Preventive health care measures before and after start of renal replacement therapy. J Gen Intern Med. 2002;17:588–595
  14. Chertow GM, Paltiel AD, Owen WF, Lazarus JM. Cost-effectiveness of cancer screening in end-stage renal disease. Arch Intern Med. 1996;156:1345–1350
  15. LeBrun CJ, Diehl LF, Abbott KC, Welch PG, Yuan CM. Life expectancy benefits of cancer screening in the end-stage renal disease population. Am J Kidney Dis. 2000;35:237–243
  16. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;4:397–409
  17. Walter LC, Lindquist K, O'Hare AM, Johansen KL. Targeting screening mammography according to life expectancy among women undergoing dialysis. Arch Intern Med. 2006;166:1203–1208
  18. Tabar L, Duffy SW, Yen MF, et al. All-cause mortality among breast cancer patients in a screening trial: Support for breast cancer mortality as an end point. J Med Screen. 2002;9:159–162
  19. The Australian Institute of Health and Welfare and the Australian Government Department of Health and Ageing for the BreastScreen Australia Program. BreastScreen Australia Monitoring Report 2001-2002. Canberra, Australia: Australian Institute of Health and Welfare; 2003;
  20. Brewer NT, Salz T, Lillie SE. Systematic review: The long-term effects of false-positive mammograms. Ann Intern Med. 2007;146:502–510
  21. Silverstein MJ, Recht A, Lagios M. Overview of Conservation Surgery and Radiation Therapy: Ductal Carcinoma In Situ. In: (ed 2). Philadelphia, PA: Lippincott Williams & Wilkins; 2002;p. 287–302
  22. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 2001;28:400–418
  23. Australia Institute of Health and Welfare, National Breast Cancer Centre. Breast Cancer in Australia: An Overview, 2006. Canberra, Australia: Australian Institute of Health and Welfare; 2006;
  24. Austalian Government Australia Institute of Health and Welfare. AR-DRG Data Cubes From 2004-2005. Canberra, Australia: Australian Government Department of Health and Ageing; 2005;
  25. Australian Government Department of Health and Ageing. Medicare Benefits Schedule Book. Canberra, Australia: Australian Government Department of Health and Ageing; 2006;
  26. Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: A cohort study of 15,183 recipients. Am J Transplant. 2007;7:2140–2151
  27. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making. 2000;20:332–342
  28. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: Evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001;19:1103–1109
  29. Harris A, Hill SR, Chin J, Li JJ, Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: A retrospective analysis 1994-2004. Med Decis Making. 2008;Mar 31 [Epub ahead of print]
  30. Quinn RR, Naimark DM, Oliver MJ, Bayoumi AM. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? (A cost-utility analysis [see comment]). Am J Kidney Dis. 2007;50:421–432
  31. Castellanos M, Varma S, Ahern K, et al. Increased breast calcifications in women with ESRD on dialysis: Implications for breast cancer screening. Am J Kidney Dis. 2006;48:301–306
  32. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: Breast cancer mortality after 11 to 16 years of follow-up (A randomized screening trial of mammography in women age 40 to 49 years). Ann Intern Med. 2002;137(Pt 1):305–312
  33. Basnakian AG, Apostolov EO, Yin X, Napirei M, Mannherz HG, Shah SV. Cisplatin nephrotoxicity is mediated by deoxyribonuclease I. J Am Soc Nephrol. 2005;16:697–702
  34. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808–3815
  35. Chapman JR, Webster AW. Cancer Report, chap 10 (The 25th Annual ANZDATA Registry Report 2002). In: Adelaide, South Australia: Australian and New Zealand Dialysis and Transplant Registry; 2003;p. 83–90
  36. Evans AJ, Cohen ME, Cohen GF. Patterns of breast calcification in patients on renal dialysis. Clin Radiol. 1992;45:343–344
  37. Brett J, Bankhead C, Henderson B, Watson E, Austoker J. The psychological impact of mammographic screening (A systematic review). Psychooncology. 2005;14:917–938
  38. Brodersen J, Thorsen H, Cockburn J. The adequacy of measurement of short and long-term consequences of false-positive screening mammography. J Med Screen. 2004;11:39–44
  39. Bloembergen WE, Port FK, Mauger EA, Wolfe RA. A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol. 1995;6:184–191
  40. Berrington de GA, Reeves G. Mammographic screening before age 50 years in the UK: Comparison of the radiation risks with the mortality benefits. Br J Cancer. 2005;93:590–596
  41. Glasziou P, Irwig L. The quality and interpretation of mammographic screening trials for women ages 40-49. J Natl Cancer Inst. 1997;22:73–77
  42. Wong G, Howard K, Craig JC, MacDonald S, Chapman JR. Cancer Report, chap 10 (The 29th Annual ANZDATA Registry Report 2006). In: Adelaide, South Australia: Australian and New Zealand Dialysis and Transplant Registry; 2006;p. 137–142
  43. Barratt AL, Les IM, Glasziou PP, Salkeld GP, Houssami N. Benefits, harms and costs of screening mammography in women 70 years and over: A systematic review. Med J Aust. 2002;176:266–271
  44. Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68:2801–2808
  45. Gudex CM. Health-related quality of life in endstage renal failure. Qual Life Res. 1995;4:359–366
  46. Kiberd BA, Keough-Ryan T, Clase CM. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am J Transplant. 2003;3:619–625
  47. Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). Special Data Request (2005). Adelaide, South Australia: Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry; 2005;
  48. Mushlin AI, Kouides RW, Shapiro DE. Estimating the accuracy of screening mammography: A meta-analysis. Am J Prev Med. 1998;14:143–153
  49. Betsill WL, Rosen PP, Lieberman PH, Robbins GF. Intraductal carcinoma (Long-term follow-up after treatment by biopsy alone). JAMA. 1978;239:1863–1867
  50. Rosen PP, Braun DW, Kinne DE. The clinical significance of pre-invasive breast carcinoma. Cancer. 1980;46(suppl 25):919–925
  51. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: Follow-up after biopsy only. Cancer. 1982;49:751–758
  52. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103:2481–2484
  53. Andersson I, Sigfusson BF. Screening for breast cancer in Malmo: A randomized trial. Recent Res Cancer Res. 1987;105:62–66
  54. Frisell J, Glas U, Hellstrom L, Somell A. Randomized mammographic screening for breast cancer in Stockholm (Design, first round results and comparisons). Breast Cancer Res Treat. 1986;8:45–54
  55. Tabar L, Gad A, Holmberg L, Ljungquist U. Significant reduction in advanced breast cancer (Results of the first seven years of mammography screening in Kopparberg, Sweden). Diagn Imaging Clin Med. 1985;54:158–164
  56. Pejavar S, Wilson LD, Haffty BG. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS+RT). Int J Radiat Oncol Biol Phys. 2006;66:1320–1327
  57. Faneyte IF, Peterse JL, Van Tinteren H, et al. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res. 2004;10:4457–4463
  58. Barratt A, Howard K, Irwig L, Salkeld G, Houssami N. Model of outcomes of screening mammography: Information to support informed choices. BMJ. 2005;330:351–356
  59. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: Correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol. 2000;53:688–696
  60. Bland KI, Menck HR, Scott-Conner CE, Morrow M, Winchester DJ, Winchester DP. The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer. 1998;83:1262–1273
  61. Cancer Institute NSW. Standard cancer treatment. https://www.treatment.cancerinstitute.org.au/cancerinstituteAccessed September 29, 2007
  62. Fassbender K, Fainsinger R, Brenneis C, Brown P, Braun T, Jacobs P. Utilization and costs of the introduction of system-wide palliative care in Alberta, 1993-2000. Palliat Med. 2005;19:513–520
  63. Guest JF, Ruiz FJ, Greener MJ, Trotman IF. Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK. Eur J Cancer Care. 2006;15:65–73

 Originally published online as doi:10.1053/j.ajkd.2008.06.015 on September 16, 2008.

PII: S0272-6386(08)01099-8

doi: 10.1053/j.ajkd.2008.06.015

American Journal of Kidney Diseases
Volume 52, Issue 5 , Pages 916-929 , November 2008

Article Tools

* Image Usage & Resolution